The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Amgen (NASDAQ:AMGN) executives outlined the company’s oncology research and development priorities and provided updates on ...

Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade ...

Eli Lilly and Company LLY is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, ...

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market last week when it introduced a cheap, ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

Telehealth company Hims & Hers unleashed a wild few days in the obesity drug market when it introduced a cheap, compounded version of Novo Nordisk’s new Wegovy pill.

Analysts say TrumpRx, the Trump administration's consumer drug-pricing site, might not deliver lower drug prices for most Americans.

Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow ...

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

Novo Nordisk A/S NVO plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to ...

Medications such as Wegovy and Zepbound will no longer be covered for weight loss, although GLP-1 drugs for diabetes will still be approved.